ALBANY, N.Y., Jan. 20, 2016 /PRNewswire/ -- AMRI
(NASDAQ: AMRI) announced today that Dawn M. Von Rohr,
will join AMRI as Sr. Vice President, API, effective January 25, 2016. Ms. Von
Rohr will report to George
Svokos, Chief Operating Officer, and will be a member of the
executive team led by President and Chief Executive Officer,
William Marth. Ms.
Von Rohr will have responsibility
for setting and implementing the strategic direction for AMRI's
growing Active Pharmaceutical Ingredient (API) business unit and
for achieving the financial results of that business, AMRI's
largest business unit.
"We are pleased to welcome Dawn to AMRI," said Mr.
Svokos. "We are confident that she brings the expertise and dynamic
leadership to define and drive the next phase of growth for the API
business and that her abilities in successfully leading a global,
commercial API business will enhance our customers' experience as
we continue to provide them with the complex API products and
services they need."
Ms. Von Rohr comes to AMRI from
Mallinckrodt Pharmaceuticals, where she was Vice President and
General Manager, Global APIs. In this role, she was part of the
executive leadership team that set the direction and executed the
successful spin-out of Mallinckrodt
from Covidien, and she successfully led a business that met and
exceeded profit targets each year. Ms. Von
Rohr brings her strategic pricing, product rationalization
and business building experience.
Ms. Von Rohr began her career
within the Quality and Research & Development Department at
Schering Plough and then began a 22-year career with Mallinckrodt
Pharmaceuticals. With a technical and business education, she
transitioned to Sales and Marketing holding increasing
responsibilities including Business Manager, Director Technology
and Business Development; Senior Global Business Director; and Vice
President and General Manager. Dawn was an extended Board Member of
the Drug, Chemical, and Associated Technologies (DCAT) Organization
from 2013 to 2015.
Ms. Von Rohr has a Bachelor of
Arts degree in Chemistry from Vanderbilt
University, and a Master of Business Administration degree
with a concentration in Marketing from Washington University in St. Louis.
About AMRI
Albany Molecular Research
Inc. (AMRI) is a global contract research and manufacturing
organization that has been working with the Life Sciences industry
to improve patient outcomes and the quality of life for more than
two decades. With locations in North
America, Europe and Asia, our key business segments
include Discovery and Development Services (DDS), Active
Pharmaceutical Ingredients (API), and Drug Product Manufacturing
(DPM). Our DDS segment provides comprehensive services from hit
identification to IND, including expertise with diverse chemistry,
library design and synthesis, in vitro biology and pharmacology,
drug metabolism and pharmacokinetics, as well as natural products.
API supports the chemical development and cGMP manufacture of
complex API, including potent, controlled substances, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-announces-executive-hire-to-lead-active-pharmaceutical-ingredients-business-300207022.html
SOURCE AMRI